Many ppl might have not understand fully today's news. It is part of the basis for 1B government funding request. See link below. I posted part of the NR as well ( not Tbp NR) Money is flowing in guys
Prepaire to target over $1B dollars in federal funding for projects aimed at Influenza, Ebola, Lassa-Fever, SARS-CoV-2, Monkeypox, and on-demand vaccines
DUBAI, UNITED ARAB EMIRATES , December 6, 2022 /
EINPresswire.com/ -- Prepaire Labs, an AI-driven biotechnology company powering drug discovery, repurposing, designing, and development, today announced the appointment of Everglade Consulting (“EverGlade”), a national consulting firm assisting biotechnology companies secure non-dilutive federal funding. Prepaire has engaged Everglade to support its efforts on multiple federal funding opportunities, given its expertise and proven successes in this field for more than a decade.
Prepaire has developed an AI-driven operating system (OS) built across diverse technologies and modalities. From integrating whole-genome sequencing with deep phenotyping to datavisualize clinical iPSC panels, the platform continuously expands massive proprietary biological and chemical datasets. Prepaire combines in-silico prediction with high throughput wet-lab validation within the HAiLO™ workflow that empowers continuous improvement and increases efficiency, accuracy, and reliability which are critical to drug R&D.
The appointment of Everglade comes on the heels of a recent application submitted to the Biomedical Advanced Research and Development Authority’s (
Barda) DRIVe ReDIRECT (Repurposing Drugs in Response to Chemical Threats) program with Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1). This Prepaire submission offers a solution to improve the management of patients exposed to pulmonary (i.e. chlorine, phosphorene) or nerve chemical agents (i.e., Sarin, Soman, or Tabun) and optimize their clinical trajectories to minimize the outcome following mass casualty events. In a chemical emergency, minutes matter, and medical countermeasures (MCM) deployment is necessary to save lives and minimize injury. With Prepaire, treatment, discovery, and production are reduced from decades to near time, avoiding lengthy and expensive trials while improving outcomes and safety.
Dr Vicent Ribas, Co-Founder & Chief Scientific Officer at Prepaire “Among public health agencies, BARDA is uniquely positioned to defend the country against future pandemics and bioweapons. The agency’s work has led to 62 medical countermeasures that have received a greenlight from the FDA. Pound for pound, BARDA has been easily the most effective federal agency in the US national COVID response. The advantages of the Prepaire operating is to accelerate the pace of discovery and innovation with our vast data sets and advanced analytics to enable faster evidence-based decision-making. These efforts unlock hidden insights and provide new and unique perspectives using artificial intelligence in previously unavailable ways to analyze appropriate new molecules and repurpose existing libraries. we have already identified dozens of federal opportunities that will benefit from these discoveries.”
Ribas continued “Everglade brings a successful track record of securing significant budgets via federal funding, allowing biotechnology clients to advance the development of drug portfolios and innovative solutions to address influenza and other infectious disease threats. We are confident in their ability to deliver multiple contracts for Prepaire in 2023 and beyond. Prepaire is already providing solutions to other governments to accelerate medical countermeasures to rapidly respond to current and future public health emergencies. We are delighted to see the span of projects open to us in the USA and looking forward to participating.”
“I am thrilled our team is able to work with Prepaire on this important initiative,” said EverGlade Founder Eric Jia-Sobota. “We look forward to continuing our track record of delivering critical funding to companies like Prepaire.”